Roots Analysis is pleased toannounce the publication of its recent study, titled, “NextGeneration Immune Checkpoint Inhibitors and StimulatorsMarket, 2020-2030.”
The report featuresan extensive study of the current market landscape, offering an informedopinion on the likely adoption of these therapies over the next decade. Itfeatures an in-depth analysis, highlighting the capabilities of various stakeholdersengaged in this domain. In addition to other elements, the study includes:
§ A detailed assessmentof the current market landscape of drug developers engaged in the developmentof next generation immune checkpoint modulators.
§ A detailed analysisof more than 590 completed, ongoing and planned clinical studies of nextgeneration immune checkpoint inhibitors and stimulators.
§ Detailed profiles ofdevelopers of next generation immune checkpoint modulators (shortlistedon the basis of the number of pipeline products).
§ An in-depth analysisof more than 490 grants that have been awarded to research institutes engagedin next generation immune checkpoint therapy-related projects.
§ An analysis of thepartnerships that have been established in this domain, in the recent past.
§ A competitivenessanalysis of biological targets, featuring insightful pictorial summaries andrepresentations.
§ An analysis of the initiativesof big biopharma players engaged in this domain.
§ A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)
- Target Disease Indication
§ Breast Cancer
§ Chronic LymphocyticLeukemia
§ Colorectal Cancer
§ Head and Neck Cancer
§ Lung Cancer
§ Lupus Nephritis
§ Melanoma
§ Multiple Myeloma
§ Primary Sjögren'sSyndrome
§ Others
- Target Immune Checkpoint
§ B7-H3
§ CD38
§ CD40
§ CD47
§ Others
- Mechanism of Action
§ Inhibitory
§ Stimulatory
- Therapeutic Modality
§ Monoclonal Antibody
§ Small Molecule
- Type of Therapy
§ Monotherapy
§ Combination Therapy
- Route of Administration
§ Intravenous
§ Subcutaneous
§ Others
- Key Geographical Region
§ North America
§ Europe
§ Asia-Pacific and theRest of the World
Key companies covered in the report
§ Bristol Myers Squibb
§ GlaxoSmithKline
§ Incyte
§ Novartis
§ Trillium Therapeutics
For more information pleaseclick on the following link:
https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Other RecentOfferings
1. NeoantigenTargeted Therapies Market, 2019-2030
2. BispecificAntibody Therapeutics Market (4th Edition),2019-2030
3. GlobalStem Cells Market: Focus on Clinical Therapies,2020-2030
About Roots Analysis
Roots Analysis is oneof the fastest growing market research companies, sharing fresh and independentperspectives in the bio-pharmaceutical industry. The in-depth research,analysis and insights are driven by an experienced leadership team which hasgained many years of significant experience in this sector. If you’d like helpwith your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots AnalysisPrivate Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
